galectin therapeutics inc (GALT) Key Developments
Galectin Therapeutics Inc. Elects Gilbert S. Omenn to its Board of Directors
Sep 24 14
On September 23, 2014, the Board of Directors of Galectin Therapeutics Inc. elected Gilbert S. Omenn, M.D., Ph.D. to its Board of Directors. Dr. Omenn served on the board of directors of Amgen Inc. for 27 years and of Rohm & Haas Company for 22 years. He currently serves on the boards of Esperion Therapeutics Inc., Etubics Corp., and OncoFusion Therapeutics Inc.
Pomerantz LLP Announces the Filing of Class Action Against Galectin Therapeutics, Inc. and Certain Officers
Sep 5 14
Pomerantz LLP has filed a class action lawsuit against Galectin Therapeutics, Inc. and certain of its officers. The class action, filed in United States District Court, District of Nevada, and docketed under 14-cv-01287, is on behalf of a class consisting of all persons or entities who purchased Galectin securities between January 6, 2014 and July 28, 2014, inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the Exchange Act). The complaint alleges that throughout the class period, defendants made false and/or misleading statements, and failed to disclose material adverse facts about the company's business, operations, prospects and performance. Specifically, during the class period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the company was utilizing the services of paid stock promoters to disseminate positive but misleading reports about Galectin's prospects; (2) moreover, GR-MD-02 did not provide the benefits suggested by Defendants when discussing the patent the company was awarded or the Phase 1 clinical trial it was conducting; and (3) as a result of the above, the company's financial statements were materially false and misleading at all relevant times.
Galectin Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 01:00 PM
Aug 30 14
Galectin Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 01:00 PM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Peter G. Traber, Chief Executive Officer, President, Chief Medical Officer and Director.
Galectin Therapeutics, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014
Aug 7 14
Galectin Therapeutics, Inc. reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total operating loss was $3.375 million compared with $2.547 million for the same period last year. Net loss applicable to common stock was $3.731 million or $0.17 basic and diluted per share compared with $11.641 million or $0.72 basic and diluted per share for the same period last year. Excluding non-cash charge, the increase in net loss applicable to common stock in the quarter ended June 30, 2014 over 2013 is primarily due to increases in clinical trial costs related to Phase 1 clinical trial, non-cash stock-based compensation expense and legal costs.
For the six months, the company reported total operating loss was $8.219 million compared with $5.755 million for the same period last year. Net loss applicable to common stock was $9.139 million or $0.42 basic and diluted per share compared with $15.113 million or $0.94 basic and diluted per share for the same period last year.
The Rosen Law Firm Files Securities Class Action Against Galectin Therapeutics, Inc
Jul 31 14
The Rosen Law Firm, P.A. announces that a class action lawsuit has been filed on behalf of purchasers of Galectin Therapeutics, Inc. securities between January 6, 2014 and July 28, 2014, inclusive asserting violations of federal securities laws. According the lawsuit, Galectin and certain of its officers and directors made false and misleading statements concerning one of its lead product candidates -- GR-MD-02 that seeks to treat the liver disease NASH.